Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00247208 · ClinicalTrials.gov registry record · Phase 3
The SOS (Stenting Of Saphenous Vein Grafts) Trial
A Phase 3 study, sponsored by North Texas Veterans Healthcare System.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT00247208 is a Phase 3 study that has completed, run by North Texas Veterans Healthcare System. The registered enrollment target is 80 participants.
The verdict
NCT00247208, a Phase 3 study, has completed, sponsored by North Texas Veterans Healthcare System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine whether implantation of a paclitaxel-eluting stent (Taxus™) in saphenous vein graft lesions will reduce the incidence of in-stent restenosis after 12 months when compared to a similar bare metal stent.
Interventions
- DEVICE Taxus polymer-based paclitaxel-eluting stent
- DEVICE Express 2 bare metal stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00247208
The ClinicalTrials.gov registry entry for NCT00247208 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is North Texas Veterans Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Taxus polymer-based paclitaxel-eluting stent is the first listed.
NCT00247208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00247208 about?
NCT00247208 is a clinical study titled "The SOS (Stenting Of Saphenous Vein Grafts) Trial". The main purpose of this study is to determine whether implantation of a paclitaxel-eluting stent (Taxus™) in saphenous vein graft lesions will reduce the incidence of in-stent restenosis after 12 months when compared to a similar bare metal stent.
What is the current status of trial NCT00247208?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2005-05. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00247208?
The interventions under investigation include: Taxus polymer-based paclitaxel-eluting stent (DEVICE), Express 2 bare metal stent (DEVICE).
Who is sponsoring clinical trial NCT00247208?
This trial is sponsored by North Texas Veterans Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.